Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)
Close on Nov 18, 2026Market cap $10.34BP/E –Yield –
Kymera Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Kymera Therapeutics's price to book ratio was 7.4× on Nov 11, 2026, against 5.1× a year earlier. Over the last 5 years it ranged from 1.5× to 7.4×, with a median of 3.7×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.4× | +1.5 |
| 2025 | Dec 31, 2025 | 5.9× | +3.0 |
| 2024 | Dec 31, 2024 | 2.9× | −0.7 |
| 2023 | Dec 29, 2023 | 3.6× | +0.9 |
| 2022 | Dec 30, 2022 | 2.7× | −4.1 |
| 2021 | Dec 31, 2021 | 6.7× | −2.6 |
| 2020 | Dec 31, 2020 | 9.4× | – |
See a number that looks wrong?